296 related articles for article (PubMed ID: 34193514)
1. Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste".
Hester R; Mazur PK; McAllister F
Clin Cancer Res; 2021 Dec; 27(23):6287-6297. PubMed ID: 34193514
[TBL] [Abstract][Full Text] [Related]
2. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy.
Hilmi M; Delaye M; Muzzolini M; Nicolle R; Cros J; Hammel P; Cardot-Ruffino V; Neuzillet C
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1129-1142. PubMed ID: 37866368
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
[TBL] [Abstract][Full Text] [Related]
4. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
[TBL] [Abstract][Full Text] [Related]
5. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
6. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.
Heumann T; Azad N
Cancer Metastasis Rev; 2021 Sep; 40(3):837-862. PubMed ID: 34591243
[TBL] [Abstract][Full Text] [Related]
7. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
8. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
9. Uncovering key targets of success for immunotherapy in pancreatic cancer.
Pretta A; Lai E; Persano M; Donisi C; Pinna G; Cimbro E; Parrino A; Spanu D; Mariani S; Liscia N; Dubois M; Migliari M; Impera V; Saba G; Pusceddu V; Puzzoni M; Ziranu P; Scartozzi M
Expert Opin Ther Targets; 2021 Nov; 25(11):987-1005. PubMed ID: 34806517
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
11. Delivering a Double Whammy: Targeting Stroma to Improve Immunotherapy Outcomes in Pancreatic Ductal Adenocarcinoma.
Lavania S
Gastroenterology; 2022 Nov; 163(5):1159-1161. PubMed ID: 36067817
[No Abstract] [Full Text] [Related]
12. Strategies for Increasing Pancreatic Tumor Immunogenicity.
Johnson BA; Yarchoan M; Lee V; Laheru DA; Jaffee EM
Clin Cancer Res; 2017 Apr; 23(7):1656-1669. PubMed ID: 28373364
[TBL] [Abstract][Full Text] [Related]
13. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.
Pandey V; Storz P
Expert Rev Anticancer Ther; 2019 Jun; 19(6):473-482. PubMed ID: 31148495
[No Abstract] [Full Text] [Related]
14. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
Tan E; El-Rayes B
J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
17. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
18. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
Ye C; Zheng L; Yuan CH
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.
Yu S; Zhang C; Xie KP
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188461. PubMed ID: 33157162
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma.
Sperb N; Tsesmelis M; Wirth T
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]